Market Research Logo

Allergic Asthma - Pipeline Review, H1 2016

Allergic Asthma - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Allergic Asthma - Pipeline Review, H1 2016’, provides an overview of the Allergic Asthma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Asthma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Allergic Asthma
The report reviews pipeline therapeutics for Allergic Asthma by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Allergic Asthma therapeutics and enlists all their major and minor projects
The report assesses Allergic Asthma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Allergic Asthma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Allergic Asthma
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Allergic Asthma pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Allergic Asthma Overview
Therapeutics Development
Pipeline Products for Allergic Asthma - Overview
Pipeline Products for Allergic Asthma - Comparative Analysis
Allergic Asthma - Therapeutics under Development by Companies
Allergic Asthma - Therapeutics under Investigation by Universities/Institutes
Allergic Asthma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Allergic Asthma - Products under Development by Companies
Allergic Asthma - Products under Investigation by Universities/Institutes
Allergic Asthma - Companies Involved in Therapeutics Development
ALK-Abello A/S
Allergopharma GmbH & Co. KG
Amgen Inc.
Aquinox Pharmaceuticals Inc.
ASIT biotech s.a.
Aslan Pharmaceuticals Pte. Ltd.
Axikin Pharmaceuticals, Inc.
Baxalta Incorporated
Chiesi Farmaceutici SpA
Circassia Pharmaceuticals Plc
CSL Limited
Fountain Biopharma Inc.
GlaxoSmithKline Plc
Hydra Biosciences, Inc.
Infinity Pharmaceuticals, Inc.
Kineta, Inc.
Mabtech Limited
Marinomed Biotechnologie GmbH
Mycenax Biotech Inc.
NeoPharm Co., Ltd.
Oxagen Limited
Panacea Biotec Limited
Peptinnovate Limited
Pharmaxis Limited
Protectimmun GmbH
Stallergenes SAS
sterna biologicals Gmbh & Co KG
Swecure AB
The International Biotechnology Center (IBC) Generium
Verona Pharma Plc
Allergic Asthma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AcTMP-1 - Drug Profile
AMG-282 - Drug Profile
AQX-1125 - Drug Profile
Arabinogalactan - Drug Profile
ASLAN-004 - Drug Profile
ASM-8 - Drug Profile
AXP-1275 - Drug Profile
beta-escin - Drug Profile
CHF-6001 - Drug Profile
CSL-311 - Drug Profile
dalazatide - Drug Profile
Drug to Inhibit PI3 Kinase Delta for Asthma - Drug Profile
duvelisib - Drug Profile
EP-67 - Drug Profile
FB-825 - Drug Profile
GNR-044 - Drug Profile
GSK-2245035 - Drug Profile
hdm-ASIT - Drug Profile
HX-100 - Drug Profile
Lactococcus lactis G121 - Drug Profile
Leukothera - Drug Profile
OC-000459 - Drug Profile
OC-2417 - Drug Profile
omalizumab biosimilar - Drug Profile
omalizumab biosimilar - Drug Profile
omalizumab biosimilar - Drug Profile
omalizumab biosimilar - Drug Profile
omalizumab biosimilar - Drug Profile
omalizumab biosimilar - Drug Profile
OND-86 - Drug Profile
pemirolast potassium - Drug Profile
pentosan polysulfate sodium - Drug Profile
PIN-201601 - Drug Profile
RPL-554 - Drug Profile
S-1226 - Drug Profile
SB-010 - Drug Profile
SG-100 - Drug Profile
SM-301 - Drug Profile
Small Molecule for Allergic Asthma - Drug Profile
Small Molecules for Allergic Asthma - Drug Profile
Small Molecules to Inhibit CaMKII for Allergic Asthma - Drug Profile
standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile
standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract - Drug Profile
SWE-01 - Drug Profile
tezepelumab - Drug Profile
Vaccine for Allergic Rhinitis and Allergic Asthma - Drug Profile
Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma - Drug Profile
Allergic Asthma - Recent Pipeline Updates
Allergic Asthma - Dormant Projects
Allergic Asthma - Discontinued Products
Allergic Asthma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Allergic Asthma, H1 2016
Number of Products under Development for Allergic Asthma - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Development by Companies, H1 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2016
Allergic Asthma - Pipeline by ALK-Abello A/S, H1 2016
Allergic Asthma - Pipeline by Allergopharma GmbH & Co. KG, H1 2016
Allergic Asthma - Pipeline by Amgen Inc., H1 2016
Allergic Asthma - Pipeline by Aquinox Pharmaceuticals Inc., H1 2016
Allergic Asthma - Pipeline by ASIT biotech s.a., H1 2016
Allergic Asthma - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2016
Allergic Asthma - Pipeline by Axikin Pharmaceuticals, Inc., H1 2016
Allergic Asthma - Pipeline by Baxalta Incorporated, H1 2016
Allergic Asthma - Pipeline by Chiesi Farmaceutici SpA, H1 2016
Allergic Asthma - Pipeline by Circassia Pharmaceuticals Plc, H1 2016
Allergic Asthma - Pipeline by CSL Limited, H1 2016
Allergic Asthma - Pipeline by Fountain Biopharma Inc., H1 2016
Allergic Asthma - Pipeline by GlaxoSmithKline Plc, H1 2016
Allergic Asthma - Pipeline by Hydra Biosciences, Inc., H1 2016
Allergic Asthma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016
Allergic Asthma - Pipeline by Kineta, Inc., H1 2016
Allergic Asthma - Pipeline by Mabtech Limited, H1 2016
Allergic Asthma - Pipeline by Marinomed Biotechnologie GmbH, H1 2016
Allergic Asthma - Pipeline by Mycenax Biotech Inc., H1 2016
Allergic Asthma - Pipeline by NeoPharm Co., Ltd., H1 2016
Allergic Asthma - Pipeline by Oxagen Limited, H1 2016
Allergic Asthma - Pipeline by Panacea Biotec Limited, H1 2016
Allergic Asthma - Pipeline by Peptinnovate Limited, H1 2016
Allergic Asthma - Pipeline by Pharmaxis Limited, H1 2016
Allergic Asthma - Pipeline by Protectimmun GmbH, H1 2016
Allergic Asthma - Pipeline by Stallergenes SAS, H1 2016
Allergic Asthma - Pipeline by sterna biologicals Gmbh & Co KG, H1 2016
Allergic Asthma - Pipeline by Swecure AB, H1 2016
Allergic Asthma - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016
Allergic Asthma - Pipeline by Verona Pharma Plc, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Allergic Asthma Therapeutics - Recent Pipeline Updates, H1 2016
Allergic Asthma - Dormant Projects, H1 2016
Allergic Asthma - Dormant Projects (Contd..1), H1 2016
Allergic Asthma - Dormant Projects (Contd..2), H1 2016
Allergic Asthma - Dormant Projects (Contd..3), H1 2016
Allergic Asthma - Discontinued Products, H1 2016
List of Figures
Number of Products under Development for Allergic Asthma, H1 2016
Number of Products under Development for Allergic Asthma - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Top 10 Routes of Administration, H1 2016
Number of Products by Stage and Top 10 Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report